STOCK TITAN

LeonaBio Inc reported a $106.0M net loss for fiscal 2025. See the full LONA financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

LeonaBio to Participate in Cantor Global Healthcare Conference 2026

LeonaBio plans a webcast fireside chat at the 2026 Cantor Global Healthcare Conference, with live access and a 30-day replay for investors.

(Moderate)
(Positive)
Tags

LeonaBio (LONA)/b) will participate in the Cantor Global Healthcare Conference 2026 in New York from September 9–11, 2026.Company management will join a fireside chat on Friday, September 11, 2026, from 9:45 am to 10:15 am EDT. A live webcast and at least 30-day replay will be available via the Investors section of LeonaBio’s website.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

Market Context

LONA’s August 12 conference announcement was followed by a 3.28% 24-hour move, giving this schedulin...
Analysis

LONA’s August 12 conference announcement was followed by a 3.28% 24-hour move, giving this scheduling notice a relevant historical comparison. It adds investor access but no disclosed data; the absence of peer activity remains a contextual risk.

Key Figures

Conference dates: September 9-11, 2026 Fireside chat time: 9:45 am-10:15 am EDT Replay availability: At least 30 days
3 metrics
Conference dates September 9-11, 2026 Cantor Global Healthcare Conference 2026
Fireside chat time 9:45 am-10:15 am EDT Friday, September 11, 2026
Replay availability At least 30 days Following the event

Historical Context

5 past events · Latest: Aug 14 (Negative)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
Aug 14 Second-quarter earnings Negative -3.2% Higher expenses, net loss, and reduced cash accompanied Phase 3 enrollment progress.
Aug 12 Breast cancer conference Positive +3.3% Lasofoxifene presentations and planned Phase 3 enrollment completion were highlighted.
Jun 04 ALS conference presentation Positive -0.2% Brelgometon development plans and Phase 1 support were presented at an ALS summit.
May 27 Industry meeting participation Positive +1.4% The company announced presentations at ALS and BIO industry meetings.
May 07 First-quarter earnings Positive +1.8% Financing resources and pipeline updates accompanied first-quarter financial results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Historical conference-related announcements produced mixed 24-hour reactions, ranging from -0.23% to +3.28%, while the latest earnings report was followed by a -3.2% move.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

BOTHELL, Wash., Sept. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that Company management will participate in the Cantor Global Healthcare Conference 2026, taking place September 9-11, 2026 in New York, NY. Details are as follows:

Cantor Global Healthcare Conference 2026
Format: Fireside Chat
Date and Time: Friday, September 11, 2026, from 9:45 am – 10:15 am EDT
Location: New York, NY

A live webcast of the fireside chat can be accessed from the Investors section of the LeonaBio website at https://investors.leonabio.com/news-and-events/events-and-presentations-investor. An archived replay will be available for at least 30 days following the event.

About LeonaBio
LeonaBio, headquartered in the Seattle, Washington area, is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS), with the goal of improving patients’ lives. Our lead drug candidates, lasofoxifene and brelgometon (ATH-1105), are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. With a strong commitment to scientific excellence and patient-centered innovation, we are dedicated to developing meaningful new therapies for those who need them most.

For more information, visit www.leonabio.com.

Investor & Media Contact:
Julie Rathbun
LeonaBio
Julie.rathbun@leonabio.com
206-769-9219


FAQ

When will LeonaBio (LONA) present at the Cantor Global Healthcare Conference 2026?

LeonaBio management will participate in a fireside chat at the Cantor Global Healthcare Conference 2026 on Friday, September 11, 2026, from 9:45 am to 10:15 am EDT in New York, NY.

What is the format of LeonaBio’s session at the Cantor Global Healthcare Conference 2026?

LeonaBio’s session at the Cantor Global Healthcare Conference 2026 will be a fireside chat with company management, scheduled for September 11, 2026, from 9:45 am to 10:15 am EDT in New York, NY.

How can investors access the LeonaBio (LONA) webcast from the Cantor Global Healthcare Conference 2026?

Investors can access a live webcast of LeonaBio’s fireside chat from the Investors section of the company’s website at https://investors.leonabio.com/news-and-events/events-and-presentations-investor.

Will a replay of LeonaBio’s Cantor Global Healthcare Conference 2026 fireside chat be available?

Yes. An archived replay of LeonaBio’s fireside chat from the Cantor Global Healthcare Conference 2026 will be available on the company’s website for at least 30 days following the event.